卡度尼利单抗致免疫性心肌炎1例  

One case of immune-mediated myocarditis induced by Cadonilimab monoclonal antibody

作　　者：丁娣 孙旭森 钱晓琳 王韦 张政 DING Di;SUN Xusen;QIAN Xiaolin;WANG Wei;ZHANG Zheng(Department of Cardiology,Qingpu Branch,Zhongshan Hospital Affiliated to Fudan University,Shanghai,201700,China)

机构地区：[1]复旦大学附属中山医院青浦分院心血管内科,上海201700

出　　处：《临床心血管病杂志》2024年第12期1029-1031,共3页Journal of Clinical Cardiology

基　　金：长三角数字干线青浦区科技发展基金项目(No:QKY2022-09)。

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已用于治疗多种恶性肿瘤,使肿瘤患者受益。卡度尼利单抗是2022年6月获批的首个PD-1/CTLA-4肿瘤双ICIs,迄今为止尚无使用卡度尼利单抗所致的ICIs相关性心肌炎的报道。本文介绍了1例使用卡度尼利单抗3个周期后诊断为重症ICIs相关性心肌炎,行糖皮质激素治疗后病情显著改善的病例。此病例强调了卡度尼利单抗诱导ICIs相关性心肌炎的潜在风险,为此类新型免疫抑制剂导致心肌炎的诊断和治疗提供思路。Immune checkpoint inhibitors(ICIs)have been used to treat various malignant tumors,and benefit cancer patients.Cadonilimab is the first PD-1/CTLA-4 tumor dual ICIs approved in June 2022,and there have been no reports of ICIs associated myocarditis caused by Cadonilimab.This article introduces one case of severe ICIs related myocarditis diagnosed after 3 cycles of using Cadonilimab,and his condition was improved significantly after glucocorticoids treatment.This case highlights the potential risk of ICIs related myocarditis induced by Cadonilimab,providing insights for the diagnosis and treatment of ICIs related myocarditis.

关 键 词：卡度尼利单抗 免疫检查点抑制剂 免疫性心肌炎 

分 类 号：R542.2[医药卫生—心血管疾病]